IXICO PLC
("IXICO" or
the "Company")
Commercial agreement with
PETNET Solutions Inc,
a Siemens Healthineers
Company
16
December 2024 - London,
UK. IXICO plc (AIM: IXI, "IXICO" or
"the Company") a global leader in
neuroscience imaging, using its AI-driven platform to help advance
therapy research in neurological disorders, today announced a
commercial agreement with PETNET Solutions Inc, a Siemens
Healthineers company ("PETNET") to supply diagnostic imaging
agents to IXICO.
This new offering is an
integral part of IXICO's expansion strategy to serve its growing
customer base with the latest technologies in
neuroimaging.
The commercial agreement will see
PETNET supplying targeted imaging agents to imaging sites used
on IXICO's customers' clinical trials. Further, the agreement adds additional capability to IXICO's
growing Tracer Management service offering which provides customers
with use guidance, logistics and seamless integration of PET
tracers in neurological clinical trials.
PETNET provides radioactive
tracers for Positron Emission Tomography ("PET scans"), a widely
used diagnostic approach that creates detailed three-dimensional
imaging, in this use case, of the inside of the brain.
Specific imaging agents may estimate β-amyloid neuritic plaque density in adult
patients who are being evaluated for Alzheimer's Disease (AD) and
other causes of cognitive decline. Another tracer estimates
the density and distribution of aggregated tau neurofibrillary
tangles (NFTs) in adult patients with cognitive impairment who are
being evaluated for Alzheimer's Disease.
Bram Goorden, Chief Executive
Officer of IXICO, commented:
''IXICO
continues to develop its end to end imaging service for clinical
trials, and we are therefore delighted to be partnering with PETNET
Solutions to provide access and supply PET tracers. This
partnership is an integral part of an expanding offering and our
commitment to positively impacting drug discovery and development
in critical neurodegenerative illnesses such as Alzheimer's
Disease.''
The announcement follows a
number of commercial agreements announced throughout 2024 including
significant clinical trial contract wins in Huntingdon Disease,
Parkinsonian Disorder and Alzheimer's Disease, an MRI algorithm
collaboration with Imeka, and a PET tracer supply agreement with
Life Molecular Imaging.
Ends
Further information:
IXICO plc
Bram Goorden, Chief Executive
Officer
+44 (0)20 3763 7499
Grant Nash, Chief Financial
Officer
This is an RNS Reach announcement,
and the information contained is not considered to have a
significant impact on management's expectations of the Group's
performance. RNS Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies
to distribute non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be
disseminated as an RNS regulatory announcement and not on RNS
Reach.
About IXICO www.IXICO.com
IXICO is dedicated to delivering
insights in neuroscience to help transform the advancement of
investigational therapies for neurological diseases, such as
Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to
advance medicine and human health by turning data into clinically
meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all
phases of CNS clinical research. IXICO's goal is to be a leading
advocate of artificial intelligence in medical image
analysis.
IXICO has developed and deployed
breakthrough data analytics, at scale, through its remote access
technology platform, to improve the return on investment in drug
development and reduce risk and uncertainty in clinical trials for
the Company's pharmaceutical clients.
